Advice

Following a full submission

dasatinib 20mg, 50mg, 70mg (Sprycel®) is not recommended for use within NHS Scotland for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.

It has been associated with haematological and cytogenetic responses in patients resistant or intolerant to existing treatment. However, the economic case was not sufficiently robust and the manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC.

Download detailed advice48KB (PDF)

Download

Medicine details

Medicine name:
dasatinib (Sprycel)
SMC ID:
371/07
Indication:
Philadelphia chromosome positive (PH+) actue lymphoblastic leukaemia
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published:
07 May 2007